Trastuzumab (Herceptin®) is a monoclonal IgG1 antibody to the human epidermal growth factor HER2/neu receptor which is indicated in the treatment of breast cancers over-expressing the HER2 receptor. This evidence concerns the gene ERBB2 and breast cancer.